^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ADCV01

    i
    Other names: ADCV01, autologous dendritic cells, ADCV 01
    Associations

    News

    Trials
    Company:
    Ever Supreme Bio Tech
    Drug class:
    T-lymphocyte cell therapy, Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    2ms
    Evaluate the Efficacy and Safety of ADCV01 As an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients (clinicaltrials.gov)
    P2, N=24, Recruiting, Ever Supreme Bio Technology Co., Ltd. | Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2022 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
    |
    IDH wild-type • PD-1-L
    |
    ADCV01
    over2years
    Evaluate the Efficacy and Safety of ADCV01 as an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients (clinicaltrials.gov)
    P2, N=24, Recruiting, Ever Supreme Bio Technology Co., Ltd. | Trial completion date: Jun 2022 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Dec 2022
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
    |
    IDH wild-type • PD-1-L
    |
    ADCV01